Acrobiosystems Co

Acrobiosystems Co Interest Coverage

The Interest Coverage Ratio of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 1.81. In the previous year, Interest Coverage Ratio was 1.90 — a change of -4.71% (lower).

Interest Coverage

1.81

YoY

-4.71%

Last updated:

Interest Coverage Ratio of Acrobiosystems Co is 2024 1.81 . Interest Coverage Ratio of Acrobiosystems Co was 2023 1.90 . It decreases by -4.71% lower compared to the previous year.

The Acrobiosystems Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
5.82 CNY
Jan 1, 2019
11.15 CNY
Jan 1, 2020
68.17 CNY
Jan 1, 2021
22.39 CNY
Jan 1, 2022
2.17 CNY
Jan 1, 2023
1.90 CNY
Jan 1, 2024
1.81 CNY
The Acrobiosystems Co Interest Coverage history
YEARInterest CoverageYoY
1.81-4.71%
1.90-12.42%
2.17-90.32%
22.39-67.15%
68.17+511.26%
11.15+91.70%
5.82—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Interest Coverage Ratio of Acrobiosystems Co is 1.81 in 2024.

Interest Coverage Ratio of Acrobiosystems Co changed from 1.90 to 1.81, representing a -4.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co